上海药物所发现纳米药物载体递送力学机制

2018-07-12 黄辛 中国科学报

中科院上海药物所甘勇课题组与国家纳米科学中心施兴华团队合作,深入解析了纳米药物载体的力学性能对于克服多重生理屏障的影响。相关成果日前在线发表于《自然—通讯》杂志。


中科院上海药物所甘勇课题组与国家纳米科学中心施兴华团队合作,深入解析了纳米药物载体的力学性能对于克服多重生理屏障的影响。相关成果日前在线发表于《自然—通讯》杂志。

纳米药物载体在到达靶细胞之前,须克服生物体内的多重生理屏障。为实现疗效最大化,设计和制备能克服多重生理屏障并具备高效细胞摄取的递送载体,成为纳米药物从实验室转向临床应用的一个重要挑战。

据了解,甘勇和施兴华前期发现,棒状粒子特有的“旋转—跳跃”运动方式能促进其在黏液中的扩散,并提出了一个考虑颗粒黏附效应的障碍—扩散理论模型。同时,双方又发现制约纳米载体口服递药和肿瘤递药的共性生理因素:具有网状结构的生物凝胶(如黏液和肿瘤细胞间质)在药物载体抵达靶细胞前扮演了重要的阻滞作用。

在最新研究中,研究人员采用微流控技术,设计制备了刚度可调的纳米药物载体,发现刚度适中的载体在生物凝胶中具有最高的扩散系数,拥有最优的细胞摄取量和药物递送能力。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1645453, encodeId=b45f164545376, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Thu Aug 02 01:13:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972182, encodeId=64e419e21826f, content=<a href='/topic/show?id=1212199e12e' target=_blank style='color:#2F92EE;'>#上海药物所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19971, encryptionId=1212199e12e, topicName=上海药物所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Thu Aug 30 18:13:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804619, encodeId=b8b71804619c0, content=<a href='/topic/show?id=20cae745155' target=_blank style='color:#2F92EE;'>#纳米药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77451, encryptionId=20cae745155, topicName=纳米药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Sep 28 09:13:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475686, encodeId=ca7814e5686f6, content=<a href='/topic/show?id=cbcce745264' target=_blank style='color:#2F92EE;'>#纳米药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77452, encryptionId=cbcce745264, topicName=纳米药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a11c7248108, createdName=xugc, createdTime=Sat Jul 14 02:13:00 CST 2018, time=2018-07-14, status=1, ipAttribution=)]
    2018-08-02 mei539
  2. [GetPortalCommentsPageByObjectIdResponse(id=1645453, encodeId=b45f164545376, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Thu Aug 02 01:13:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972182, encodeId=64e419e21826f, content=<a href='/topic/show?id=1212199e12e' target=_blank style='color:#2F92EE;'>#上海药物所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19971, encryptionId=1212199e12e, topicName=上海药物所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Thu Aug 30 18:13:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804619, encodeId=b8b71804619c0, content=<a href='/topic/show?id=20cae745155' target=_blank style='color:#2F92EE;'>#纳米药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77451, encryptionId=20cae745155, topicName=纳米药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Sep 28 09:13:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475686, encodeId=ca7814e5686f6, content=<a href='/topic/show?id=cbcce745264' target=_blank style='color:#2F92EE;'>#纳米药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77452, encryptionId=cbcce745264, topicName=纳米药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a11c7248108, createdName=xugc, createdTime=Sat Jul 14 02:13:00 CST 2018, time=2018-07-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1645453, encodeId=b45f164545376, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Thu Aug 02 01:13:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972182, encodeId=64e419e21826f, content=<a href='/topic/show?id=1212199e12e' target=_blank style='color:#2F92EE;'>#上海药物所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19971, encryptionId=1212199e12e, topicName=上海药物所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Thu Aug 30 18:13:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804619, encodeId=b8b71804619c0, content=<a href='/topic/show?id=20cae745155' target=_blank style='color:#2F92EE;'>#纳米药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77451, encryptionId=20cae745155, topicName=纳米药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Sep 28 09:13:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475686, encodeId=ca7814e5686f6, content=<a href='/topic/show?id=cbcce745264' target=_blank style='color:#2F92EE;'>#纳米药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77452, encryptionId=cbcce745264, topicName=纳米药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a11c7248108, createdName=xugc, createdTime=Sat Jul 14 02:13:00 CST 2018, time=2018-07-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1645453, encodeId=b45f164545376, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Thu Aug 02 01:13:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972182, encodeId=64e419e21826f, content=<a href='/topic/show?id=1212199e12e' target=_blank style='color:#2F92EE;'>#上海药物所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19971, encryptionId=1212199e12e, topicName=上海药物所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Thu Aug 30 18:13:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804619, encodeId=b8b71804619c0, content=<a href='/topic/show?id=20cae745155' target=_blank style='color:#2F92EE;'>#纳米药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77451, encryptionId=20cae745155, topicName=纳米药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Sep 28 09:13:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475686, encodeId=ca7814e5686f6, content=<a href='/topic/show?id=cbcce745264' target=_blank style='color:#2F92EE;'>#纳米药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77452, encryptionId=cbcce745264, topicName=纳米药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a11c7248108, createdName=xugc, createdTime=Sat Jul 14 02:13:00 CST 2018, time=2018-07-14, status=1, ipAttribution=)]
    2018-07-14 xugc

相关资讯

Adv Mater:报道华东理工一氧化氮抗肿瘤纳米药物研究新进展

李永生教授团队在一氧化氮(NO)抗肿瘤纳米药物领域研究取得新进展,相关工作成果以“Dual intratumoral redox/enzyme-responsive NO-releasing nanomedicine for the specific, high-efficacy and low-toxic cancer therapy”为题,在线发表于Advanced Materials上。

ACS Nano:暨南大学陈填烽教授研究组发现用于肿瘤同步放化疗的纳米药物

2017年5月3日,美国化学会旗下著名期刊《ACS Nano》杂志在线发表了暨南大学化学与材料学院陈填烽教授和中国科学院深圳先进技术研究院喻学锋研究员合作的一篇研究论文,研究报道了靶向纳米载药体系研究进展,本研究设计合成了一种核壳结构的靶向纳米复合体系,从而实现了肿瘤靶向的放化疗法。陈填烽课题组在前期工作中,以多种蛋白、多糖、多肽及小分子作为修饰剂,合成了多个系列不同形貌的纳米硒(SeNPs),并

ACS Nano:暨南大学陈填烽课题组发现用于肿瘤同步放化疗的纳米药物

近日,暨南大学化学与材料学院陈填烽教授和中国科学院深圳先进技术研究院喻学锋研究员合作,在靶向纳米载药体系研究中取得重要进展,设计合成了一种核壳结构的靶向纳米复合体系,从而实现了肿瘤靶向的放化疗法

此项研究成果发表在纳米领域顶级期刊ACS Nano(IF =13.334)上,研究工作得到了***万人计划青年拔尖人才项目、国家高技术研究发展计划(863计划)项目、国家自然科学基金及广东省自然科学杰出青年基金等项目的资助。

陈填烽课题组在前期工作中,以多种蛋白、多糖、多肽及小分子作为修饰剂,合成了多个系列不同形貌的纳米硒(SeNPs),并用其为载体来负载 · 2017-05-27

-->

Sci Tran Med:突破!纳米药物可治疗心脏疾病

近年来,纳米颗粒已被用于载药系统,负责将药物输送到身体的特定部位。这种疗法通常是口服或静脉注射,但往往心脏药物输送效率低下。为此,研究人员开发出了一种可吸入式纳米药物,这使得它们能够更快地到达心脏并被心肌细胞吸收,最终改善心脏功能。

Macromol Biosci:如何制备靶向效率更高的纳米药物?

化疗是一种重要的癌症治疗手段,但是化疗药物往往具有严重的毒副作用且很难达到令人满意的治疗效果,因而其在临床上的应用仍有待改善。肿瘤靶向药物递送是一种极具潜力的新型治疗手段,该类技术能有效增加化疗药物在靶部位的浓度同时降低其在健康组织器官内的蓄积,最终提高化疗的疗效和安全性。在众多靶向药物递送载体中,聚合物胶束是目前应用最广泛且最成功的载体之一。聚合物胶束是由两亲性嵌段共聚物通过自组装形成的纳米级药

Small:多管齐下,基于白蛋白的肿瘤多重响应性纳米药物

响应性纳米药物在肿瘤治疗中具有重要价值。一方面,肿瘤响应性纳米药物通过对肿瘤组织和细胞的识别,降低药物对正常组织的毒副作用;另一方面通过在肿瘤中响应性释放药物,提高治疗效果。尤其是对于光动力治疗(PDT),纳米剂型中光敏剂的单线态氧产生能力受到抑制,无法发挥PDT的作用,必须在肿瘤组织或细胞中快速释放,恢复单线态氧的产生能力和对细胞的杀伤作用。与正常组织相比,肿瘤具备pH值偏低、谷胱甘肽(GSH)